Kak..massive potential ?... so you see what Big Pharmas see ?
A good starting point is Novartis valuing Gamida Cell (currently conducting two Phase I/II trials) at $233m (15% for $35m).
How would you value 12 applications in P2 ( 3currently in Phase III) ?
...there will come a point where it so compelling that it will be clear to all that MSB is undervalued.
DYOR.
Novartis stem cell action, page-16
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43856 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 66000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |